Diabetes

views updated

Diabetes

Definition

Diabetes is the Greek term for "passing through," a phrase used to describe multiple diseases characterized by excessive urination. There are multiple forms of diabetes. The most frequently described is diabetes mellitus, a chronic disorder involving the body's use of blood glucose (blood sugar) and the synthesis, or utility, of the hormone insulin. However, not all forms of diabetes involve glucose or insulin.

Description

Diabetes is a term used to describe multiple distinctive disorders that have the symptom of excessive urination in common. Although there are multiple forms of diabetes, the most common form is diabetes mellitus.

Diabetes mellitus

Diabetes mellitus is a chronic disorder of carbohydrate (sugar) metabolism. The word "mellitus" is Latin for "honey." Diabetes mellitus is characterized by abnormal, excessive levels of the sugar glucose in the blood, which is consequently passed through the urine. Most people always have some glucose in the blood to be used by cells for energy. Blood glucose originates from food ingested, the liver, and muscle cells. However, an excessive amount of glucose chronically present in the blood causes a variety of serious health complications.

Diabetics have excessive blood glucose because of a deficiency in the production or utilization of the hormone insulin. Insulin is made by the beta cells of the pancreas in response to the elevated glucose in the blood after a meal. Insulin binds to receptors on the body's cells to allow the passage of glucose into the cell as an energy source. Insulin stimulates cells to remove glucose from the blood, stimulates the liver to metabolize glucose, and thus causes the blood sugar level to return to normal. Diabetics have either a deficiency of insulin or defective insulin receptor binding. As a result, the cells of the body are unable to receive the glucose energy and are essentially starved, despite the energy source present in the blood. Because glucose is not entering the cells, it remains in the blood causing high blood sugar, or hyperglycemia. Chronic diabetes mellitus can lead to serious problems with the eyes, kidneys, nervous system, gums, and teeth. One of the most serious complications caused by diabetes is heart disease. Diabetics are more than twice as likely to develop cardiac disease or a stroke. The risk for diabetics equals that of an individual with a history of heart attacks. The use of cigarettes greatly increases the risk for vascular disease, nerve damage, and limb amputation.

Diabetes mellitus is divided into three main subtypes known as type I diabetes, type II diabetes, and gestational diabetes. Individuals can also develop a condition known as pre-diabetes that may develop into type II diabetes.

Type I diabetes was formerly called juvenile diabetes because it is usually first identified in children or young adults. It was also known as brittle diabetes and insulin-dependent diabetes mellitus (IDDM). Type I diabetes is an autoimmune condition in which the body's immune system has attacked and destroyed the beta cells of the pancreas. As a result there is a shortage of insulin, and glucose cannot enter the cells. Bodily processes involving the storage of glucose as energy and the utilization of glucose are adversely affected. The body is essentially starved of the energy it needs for normal function.

Type II diabetes was formerly called adult-onset diabetes because it usually develops in people over the age of 40 years. However, individuals can develop type II diabetes at any age. Also known as non-insulin-dependent diabetes, type II diabetes is the most common form. Type II diabetes is a condition in which the body's cells become insulin resistant and do not properly utilize the insulin being synthesized and secreted by the pancreas. In the beginning stages, the pancreas increases insulin production in response to the increased demand. However, as the disease progresses, the pancreas loses the ability to secrete sufficient insulin in response to meals.

The third subtype of diabetes mellitus is gestational diabetes. This is a form of glucose intolerance that may develop during the late stages of pregnancy. Pregnancy hormones or an insulin deficiency may cause gestational diabetes. During pregnancy, gestational diabetes requires treatment to normalize maternal blood glucose levels and avoid complications in the infant. Gestational diabetes usually disappears after the infant is born. However, females who have had gestational diabetes are more likely to develop type II diabetes in their later years.

Pre-diabetes is a condition in which blood glucose levels are abnormally elevated, but not enough for a diagnosis of diabetes. This term is used to distinguish individuals who are at increased risk of developing diabetes type II. Individuals with pre-diabetes have impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both. IFG is a condition in which the fasting blood sugar level is elevated to a level between 100 and 125 mg/dL after an overnight fast, a value that is not high enough to be classified as diabetes. IGT is a condition in which the blood sugar level is elevated to between 140 and 199 mg/dL after a two-hour oral glucose tolerance test, a value that is not high enough to be classified as diabetes. Those individuals with pre-diabetes are at increased risk for developing type II diabetes, cardiac disease, and stroke. The risk of progressing into type II diabetes can be significantly lowered with moderate weight loss and physical activity.

Diabetes insipidus

Diabetes insipidus is caused when the pituitary gland does not produce enough antidiuretic hormone (ADH), which is responsible for water reabsorption in the kidney. Without sufficient ADH, an abnormal amount of water is secreted in the urine. This results in excessive urination, thirst, weakness, and dry skin. In many cases, the cause of diabetes insipidus is unknown but may involve damage to the pituitary gland by head trauma or a tumor. In some cases, it is treatable with ADH replacement therapy.

Diabetes bronze

Diabetes bronze is a rare disease of iron metabolism that occurs in conjunction with diabetes mellitus and cardiac failure. It usually develops after 40 years. Diabetes bronze is characterized by the usual symptoms of diabetes mellitus with the addition of an enlarged liver and hyperpigmentation of the skin to a bronze color. It occurs 10 times as frequently in males than in females.

Genetic profile

Type I and type II diabetes mellitus have different causes, yet both have genetic components. A combination of inheriting a predisposition to diabetes and environmental trigger factors may make the biggest contribution to the development of the disease. A genetic predisposition contributes to, but does not automatically result, in diabetes. Studies of identical twins show that when one twin has type I diabetes mellitus, the other develops the disease about 50% of the time. When one twin has type II diabetes, the other develops the disease about 75% of the time.

Type I diabetes is an autoimmune disorder in which the immune system attacks the insulin-secreting pancreatic beta cells. The onset of type I diabetes is attributed to both inherited risk and external triggers, such as improper diet or an infection. Approximately 18 regions of the genome have been linked with risk for diabetes type I. These regions may each contain several genes that have abnormal variations in some diabetics. They are labeled IDDM1 to IDDM18.

The region, or locus, most well studied is IDDM1. IDDM1 contains genes that encode immune response proteins called the HLA genes. Variations in HLA genes are one of multiple important genetic risk factors. Normal HLA genes encode for proteins called major histocompatibility complex (MHC), which assemble on the cell surface, are viewed by the immune system as "self," and therefore are not attacked. When there are variations in the HLA genes, they encode for variable MHC proteins expressed on the cell surface. The pancreatic beta cells of some diabetics have variable MHC proteins that the immune system does not recognize as self, and attacks as it would a virus or bacteria. The IDDM1 gene locus contains these variations in HLA genes that cause the pancreatic beta cells to be attacked and destroyed by the immune system.

The inheritance of particular HLA gene variations can account for more than 50% of the genetic risk of developing type I diabetes. The genes most strongly linked with diabetes are called HLA-DR, HLA-DQ, and HLA-DP. Half of the general population inherits a copy, called an allele, of the HLA-DR gene called DR3 or DR4. Less than 3% of the general population has both alleles. However, 95% of Caucasians with type I diabetes possesses at least one allele of DR3 or DR4. Individuals with both alleles are at the highest risk of developing type I diabetes mellitus. Conversely, the HLA-DR2 allele has protective effect and lowers the risk of developing diabetes.

As seen with the DR gene, specific alleles of the DQ gene are risk factors for developing type I diabetes, and specific alleles are protective. There is a tendency for individuals who inherit DR3 or DR4 to inherit a variant of DQ that increases their genetic risk of developing type I diabetes. The protective DR and DQ alleles also tend to be inherited together. These combination tendencies are not absolute, a phenomenon known as linkage disequilibrium. The IDDM1 locus contains many diabetes susceptibility genes that exhibit linkage disequilibrium, making it difficult to research the effects of any one gene on diabetes susceptibility.

The IDDM2 locus contains the insulin gene (INS) that is located on chromosome 11. Mutations of INS cause a rare form of diabetes that is similar to MODY. Other variations of the insulin gene may contribute to susceptibility to type I and II diabetes. The IDDM2 locus contributes about 10% toward type I diabetes susceptibility incidence. The type I diabetes risk associated area of this locus is localized to a region flanking the insulin gene that contains a short sequence of DNA that is repeated many times. The repeated sequences follow one behind the other (in tandem) and the number of repeats is variable between individuals, an event called a variable number tandem repeat (VNTR). There are three classes of VNTR in the insulin gene.

Class I has alleles that range 26–63 repeat units, class II has alleles with approximately 80 repeat units, and class III has alleles ranging 141–209 repeat units. In Caucasians, who have the highest rate of type I diabetes, the class-I VNTRs are most common. Class I alleles are responsible for 70% of the VNTR alleles, with nearly all the other alleles being class III. The short class I alleles are associated with a higher risk of developing type I diabetes, whereas the longer class III alleles are protective. The presence of at least one class III allele is associated with a threefold reduction in the risk of type I diabetes. Class III VNTR alleles are associated with higher levels of insulin in the thymus. The thymus gland has an important role in training the immune system to not attack the body's own cells. Immature immune cells called T cells are presented with chains of amino acids, such as insulin, to recognize as self. Any T cells that form a response to them, to attack them, are deleted to prevent autoimmunity. Because the longer VNTRs cause more insulin to be produced in the thymus, the detection and deletion of autoreactive T cells that would attack the body's cells may be more efficient. The resulting improved immune tolerance to insulin would lessen the risk of a future onset of type I diabetes caused by anti-insulin immune responses.

There is conflicting evidence for the role of INS in predisposition to type II diabetes. Certain mutations in INS can result in mutant insulin that results in rare forms of diabetes. One type of mutant insulin, called Chicago insulin, has been found in individuals who have a rare form of diabetes that resembles MODY. This form of diabetes is caused by a single gene mutation and is inherited in an autosomal dominant fashion. The INSR gene encodes the receptor for insulin. Mutations of the insulin receptor can also cause rare forms of diabetes and may play a role in susceptibility to type II diabetes. However, most diabetics have a normal sequence of the insulin receptor, indicating that if insulin receptor mutations contribute to the development of type II diabetes, they will be present only in a minor fraction of the diabetic population.

In determining the risk of developing type II diabetes mellitus, environmental factors such as diet and exercise play an important role. The majority of individuals with type II diabetes are either overweight or obese. Inherited factors are also keys to the development of type II diabetes. However, as of 2004 the multiple genes involved remained poorly defined. Genes that have been implicated may have only subtle variations that are extremely common, known as single nucleotide polymorphisms (SNPs). It is very difficult to link common gene variations with an increased risk of developing diabetes. Many of the links that have been found seem to be important in only select ethnic or geographical populations.

Calpain 10 (CAPN10) is one such gene that maps to chromosome 2. CAPN10 is a calcium-activated enzyme that breaks down proteins. SNPs in part of the CAPN10 gene are associated with a threefold increased risk of type II diabetes in Mexican Americans. It is thought that these genetic variants of CAPN10 may alter pancreatic beta cell survival, insulin production, insulin action, and liver glucose production. CAPN10 may also be involved in development of type II diabetes in Chinese populations. However, in European, Japanese, and Samoan populations, CAPN10 does not appear to play an important role.

The HFN4A gene encodes a transcription factor that is found in the liver and pancreas. HNF4A maps to a region of chromosome 20 that is linked with type II diabetes. HNF4A mutations cause a rare form of autosomal dominant diabetes. The HNF4A gene is now also being researched for involvement in predisposition to type II diabetes. It is thought that pancreatic beta cells are responsive to the amount of HNF4A present to regulate insulin production. SNPs in HNF4A have an impact on pancreatic beta cell function, increasing or decreasing insulin secretion. In the British population, individuals with SNPs that cause increased insulin secretion capacity have a reduced risk for diabetes. In the Ashkenazi Jewish population and Finnish population, four SNPs near the HNF4A gene have been identified as associated with type II diabetes via an unknown mechanism that may cause pancreatic beta cell malfunction.

In 2004, research began on various other genes that are candidates for type II diabetes predisposition in specific populations, many of which reside on various IDDM loci. The ABCC8 gene encodes the receptor for sulfonylurea. Sulfonylureas are a class of drug used to lower blood glucose levels in type II diabetics by inter-acting with the sulfonylurea receptor of pancreatic beta cells and stimulating insulin release. Genetic variations of ABCC8 may impair the release of insulin in some diabetics. The GCGR gene encodes the hormone glucagon, which regulates glucose levels. A mutation in GCGR has been associated with type II diabetes in the French and Sardinian population. The GCK gene encodes for the enzyme glucokinase, which speeds up glucose metabolism and acts as a glucose detector in pancreatic beta cells. Mutant glucokinase causes a rare form of diabetes and may also play a role in type II diabetes in some populations. Mutations known to activate glucokinase are all clustered in one area of the glucokinase structure that is called the allosteric activator site. These mutations cause an increase in insulin release. Research is being performed to discover pharmacological agents that act as allosteric activators to increase glucokinase activity, increase the release of insulin, and can be used in the treatment of diabetes. Because glucokinase activators also stimulate liver glucose metabolism, they would be doubly effective in reducing the blood sugar of diabetics. The GLUT2 gene encodes a glucose transporter which controls the entry of glucose into pancreatic beta cells and detects blood glucose. Mutations of GLUT2 cause a rare genetic syndrome that disturbs blood glucose control. Common variants of GLUT2 may also be linked with type II diabetes. The KCNJ11 gene encodes a potassium ion channel on the surface of pancreatic beta cells. Closure of potassium channels in these cells triggers insulin release. Pharmacological agents that close the channels are used in the treatment of diabetes.

Variations in KCNJ11 have been linked to both increased and decreased insulin release. A controlled study done in non-diabetic adults with a SNP in KCNJ11 demonstrated that the variation was associated with impaired insulin release in response to glucose and increased body mass index (BMI). Lipoprotein lipase (LPL) is an enzyme that breaks down triglycerides. LPL is functionally impaired or present at low levels in many type II diabetics. Evidence suggests that insulin may help regulate LPL synthesis. A common complication of type II diabetes is protein excreted in the urine because of chronic inflammation and kidney damage. There is a correlation between the severity of this condition and genetic variation in LPL. SNPs in the LPL gene are associated with insulin resistance in Mexican Americans. The same variation is associated with coronary artery disease, and may provide some of the link between diabetes and atherosclerosis.

An important diabetes risk factor and drug target is peroxisome proliferator activated receptor gamma (PPARc). This protein is a transcription factor that regulates fat cell development. Diabetics are prescribed drugs that activate PPARc to increase insulin sensitivity and lower blood sugar. Variations in PPARc influence the risk of developing obesity and type II diabetes. A common variation at position 12 confers a small risk of developing obesity of about 1.3% increase. For the individual, this 1.3% is a small increase of risk, but 75% of the population has this variation, which translates into a large impact on the prevalence of diabetes. The Pima Indians of Arizona, a population known for type II diabetes incidence, contain several SNPs in the gene for PPARc. There are other SNPs in the gene for PPARc that confer a degree of protection against insulin resistance and obesity. Mutations in some of these genes may also lead to a rare form of diabetes known as MODY (maturity-onset diabetes of the young). MODY is inherited in an autosomal dominant fashion. It is similar to non-insulin dependent diabetes, but develops in individuals before the age of 25.

Environmental triggers for type I diabetes are varied. Type I diabetes develops more often in cold climates than warm climates. Type I diabetes is less common in individuals who were breastfed and those whose first solid foods were at later ages. A family history of type II diabetes is only a strong risk factor for individuals living a western lifestyle of high fat diets with little exercise. Individuals who live in areas that do not have westernized lifestyles tend not to develop type II diabetes no matter how high their genetic risk. Obesity is a strong risk factor for type II diabetes; the highest environmental risk is correlated with obesity at early age or for extended periods of time. Women who develop gestational diabetes are likely to have a maternal family history of type II diabetes. The environmental factors that predispose to gestational diabetes are older age and higher weight. The ethnic group in the United States with the highest risk for type I diabetes is Caucasian. The ethnic groups in the United States with the highest risk for type II diabetes are African Americans, Mexican Americans, and Pima Indians.

Demographics

According to the American Diabetes Association, the number of individuals with diabetes in the United States in the year 2002 reached 6.3% of the population, or 18.2 million. This statistic included 210,000 individuals under the age of 20. The risk for death among individuals with diabetes is approximately two times that of non-diabetics. In 2002 research, cardiac disease and stroke were determined to be the leading cause of diabetes-related mortality, responsible for 65% of deaths. Diabetic adults have two to four times increased risk for both cardiac disease and stroke than non-diabetics. Approximately 73% of adult diabetics have elevated blood pressure or use prescription medication for hypertension. The leading cause of new cases of adult blindness from 20–74 years of age is diabetic retinopathy. Approximately 60–70% of diabetics have some degree of nervous system damage called neuropathy. Severe forms of diabetic neuropathy account for more than 60% of non-traumatic lower-limb amputations in the United States.

Preexisting diabetes that is unsuccessfully controlled before conception and during the first trimester of pregnancy can result in major birth defects in 5–10% of pregnancies and spontaneous abortions in 15–20% of pregnancies. If diabetes is unsuccessfully controlled during the second and third trimesters of pregnancy, it can cause high infant birth weight that poses a risk to both mother and child. Gestational diabetes occurs most frequently in African-American, Hispanic or Latino-American, and Native American populations. It is most common among obese women with a family history of diabetes. Women who have gestational diabetes have a 20–50% chance of developing type II diabetes within 5–10 years.

Type II diabetes is associated with obesity, family history of diabetes, prior history of gestational diabetes, impaired glucose tolerance, physical inactivity, older age, and specific ethnicities. According to the Surgeon General, gaining between 11–18 lbs (4.9–8 kgs) above normal weight doubles the risk of developing type II diabetes. Type II diabetes is increasingly diagnosed in children and adolescents, and is most common in females. African-American, Hispanic or Latino-American, Native American, and some Asian-American, native Hawaiian, or other Pacific Islander populations are particularly at high risk for type II diabetes.

By 2002, 8.4% of non-Hispanic Caucasians (12.5 million) over 20 years of age had diabetes. Regional studies done in 2002 indicated that type II diabetes is becoming more common among Native American, African-American, and Hispanic and Latino children and adolescents. Approximately 11.4% of non-Hispanic blacks (2.7 million) over 20 years of age had diabetes. Generally, non-Hispanic blacks are 1.6 times more likely to develop diabetes than non-Hispanic Caucasians. Approximately 8.2% of Hispanic or Latino Americans (2 million) over 20 years of age had diabetes. Generally, Hispanic or Latino Americans are 1.5 times more likely to have diabetes than non-Hispanic Caucasians. Mexican Americans, the largest Hispanic or Latino subgroup, are more than twice as likely to have diabetes than non-Hispanic Caucasians. Correspondingly, residents of Puerto Rico are 1.8 times more likely to be diagnosed with diabetes than non-Hispanic Caucasians in the United States. Approximately 14.5% of Native Americans and Alaskan natives (107,775) who receive care from the Indian Health Service (IHS) over 20 years of age had diabetes. Within this ethnic group, diabetes is least common among Alaskan natives (6.8%) and most common among Native Americans of the southeastern United States (27%). However, Native Americans and Alaska natives generally have 2.2 times increased risk of developing diabetes than non-Hispanic Caucasians. Native Hawaiians, Japanese, and Filipino residents of Hawaii had approximately two times increased risk to be diagnosed with diabetes than Caucasian residents of Hawaii.

Type I diabetes accounts for 5–10% of diabetes cases, and affects approximately one in every 400–500 children and adolescents. Type II diabetes accounts for 90–95% of all diabetes. This form of diabetes may remain undiagnosed for many years. Increased awareness has led to a rapid rise in the number of cases diagnosed each year, in what has been described as epidemic proportions in the United States. In 1990, 4.9% of the American population was diagnosed with diabetes. In 2001, this proportion increased to 7.9%. In the year 2002, the NIH estimated that diabetes costs more than $130 billion in total health care and was the fifth leading cause of death. According to the CDC, from the year 1980 through 2002, the proportion of diabetic Americans increased from 5.8 million to 13.3 million individuals. Estimates revealed that of the children with birth year 2000, one in three will develop diabetes over their lifetime. According to the CDC, more than 1.3 million adults between 18 and 79 years of age were diagnosed as new cases of diabetes in 2003. The CDC estimates that from 1997 to the year 2003, the number of new cases of diagnosed diabetes increased by 52%. Diabetes is predicted to become one of the most common diseases in the world within decades, affecting at least half a billion individuals.

Type I diabetes may cause the sudden onset of any of the following symptoms:

  • increased thirst, especially for sweet beverages
  • increased urination
  • weight loss, despite increased appetite
  • nausea or vomiting
  • abdominal pain
  • fatigue
  • absence of menstruation

Type II diabetes may proceed for long periods of time with no symptoms. When diabetes is present, symptoms include the following:

  • increased thirst, especially for sweet beverages
  • increased urination
  • increased appetite
  • fatigue
  • blurred vision
  • frequent or slow-healing infections (including urinary tract, vaginal, skin)
  • dry, itchy skin
  • tingling or numbness in hands or feet
  • erectile dysfunction in men

Diabetes mellitus impacts many organ systems and can result in many complications. Diabetic ketoacidosis (DKA) is a complication of diabetes caused by the buildup of byproducts of fat metabolism called ketones. Ketone buildup occurs when glucose is not available as a fuel source. Diabetics have a deficiency of the insulin hormone used to metabolize glucose for energy. Because glucose is not being made available for cells to use as energy, body fat is alternatively metabolized. The byproducts of fat metabolism are ketones. The ketones accumulate in the blood and so become present in the urine. DKA develops when ketones are in high enough amounts to cause the blood to acidify. In response, the liver begins releasing glucose to use as an energy source instead of fatty acids. Because the cells cannot take in this glucose in the absence of insulin, it only further elevates the blood glucose level. DKA may be the first symptom that leads to the initial diagnosis of type I diabetes. It may also be a sign that a diagnosed type I diabetic is developing a need for increased insulin. Type I diabetics are more prone to the development of DKA than type II diabetics. In a type I diabetic, DKA can result from infection, trauma, heart attack, or surgery. Type II diabetics usually develop ketoacidosis incidentally under conditions of severe stress. Recurrent episodes of DKA in type II diabetics are usually the result of poor compliance with treatment or diet.

The symptoms of DKA may include the following:

  • fruity breath odor
  • fatigue
  • appetite loss, nausea, or vomiting
  • rapid deep breathing
  • difficulty breathing, especially when lying down
  • decreased consciousness
  • mental stupor that may progress to coma
  • muscular stiffness or aching
  • headache
  • low blood pressure

Diabetics may endure periods of hypoglycemia if their blood sugar is unsuccessfully controlled or if they imbibe even small amounts of alcohol. Hypoglycemia is a low level of blood glucose that occurs when the balance between insulin, food intake, and physical exertion is disturbed. Symptoms of mild hypoglycemia include hunger, sweating, anxiety, and increased heart rate. Severe hypoglycemia can lead to a confused mental state, slurred speech, weakness, lack of coordination, dizziness, drowsiness, and loss of consciousness. The loss of consciousness due to low levels of blood sugar is called a hypoglycemic coma.

Diabetics are prone to infections from even simple lacerations. Damage to the peripheral nervous system, called diabetic peripheral neuropathy, may result in decreased blood flow and loss of sensation to the limbs. When there is loss of sensation to the feet, an infection developing from a laceration may go unnoticed and therefore not be properly cared for. Diabetics also have decreased immune defenses with which to fight infection. Because of lack of peripheral sensation, deficient oxygen supply from decreased blood flow, and reduced immune defense, diabetics are prone to developing peripheral gangrene. Small cuts with infections can rapidly progress to death of the tissue, which may require amputation of the affected limb to preserve the life of the patient. Gangrene is responsible for many limb amputations in diabetics. Diabetic individuals are advised to keep their feet clean and dry, and to thoroughly inspect daily for any sign of injury or infection.

Poorly controlled blood sugar also predisposes diabetics to fungal infections of the skin, nails, female genital tract, and urinary tract. Diabetic nephropathy is kidney disease that may occur early in diabetes. Diabetics tend to have severe urinary tract infections and are prone to kidney damage as a result. Diabetics also have an increased vulnerability to kidney damage from high blood pressure. Late-stage kidney disease may display symptoms that result from excessive protein in the urine. These symptoms include swelling around the eyes in the morning, swelling of the legs, unintentional weight gain from fluid accumulation, poor appetite, fatigue, headache, and frequent hiccups.

Diabetic retinopathy develops in 80% of diabetics after 15 years with the disease. Diabetic retinopathy is damage to capillary blood vessels that nourish the retina of the eye due to the effects of poorly controlled blood

sugar. Signs of diabetic retinopathy include decreased visual acuity and floating spots within the field of vision. Diabetics may also develop cataracts, which are clouding of the lens of the eye that develop slowly and painlessly with increasing visual difficulty. The signs of cataracts include cloudy vision and difficulty with night driving due to glare from bright lights. Initially, most diabetics experience only mild vision problems. However, both diabetic neuropathy and cataracts can progress into blindness. Diabetic retinopathy is a leading cause of legal blindness among adults in the United States. The best defense against severe vision loss is early detection and treatment via annual eye examinations, and steps to maintain control over blood sugar, blood pressure, and blood cholesterol.

Diagnosis

Type II diabetes is diagnosed with the following blood tests:

  • Fasting blood glucose test (FGT): positive diagnosis of diabetes or pre-diabetes requires values higher than 126 mg/dL after eight hours of fasting on two separate occasions.
  • Random (non-fasting) blood glucose: values higher than 200 mg/dL, accompanied by increased thirst, urination, and fatigue, cause suspicion of diabetes that must be confirmed with a fasting blood glucose test.
  • Oral glucose tolerance test (OGTT): positive diagnosis of diabetes or pre-diabetes requires values higher than 200 mg/dL two hours after consuming a glucose solution.

A positive diagnosis of diabetes requires positive results on any one of the three listed tests, with confirmation from a second positive test on a different day. The fasting plasma glucose test is preferred for diagnosing type I and type II diabetes, and pre-diabetes. This convenient test is most reliably performed in the morning after eight hours of fasting, on two separate occasions. FGT values from 70–99 mg/dL are considered normal. Fasting glucose levels of 100–125 mg/dL may indicate a form of pre-diabetes called impaired fasting glucose (IFG). Individuals with IFG have an increased probability of developing type II diabetes in the future. A fasting glucose level 126 mg/dL, in conjunction with a positive OGTT on a separate testing occasion, indicates diabetes.

The random (non-fasting) glucose test can be performed at any time of day, regardless of previous food intake. Diabetes is suspected when blood glucose levels above 200 mg/dL are present in combination with classic diabetic symptoms such as increased thirst and urination, and fatigue. Diagnosis of diabetes requires a positive fasting blood glucose test or oral glucose tolerance test to be performed on a different occasion.

The oral glucose tolerance test can be used to diagnose diabetes or pre-diabetes. The patient is required to fast for eight hours and then drink a solution containing 2.6 oz (75 g) of glucose dissolved in water. Blood glucose levels are then measured at separate points over a three-hour time interval. A value less than 140 mg/dL is considered normal. Values from 140–200 mg/dL may indicate pre-diabetes. A value over 200 mg/dL, in conjunction with a positive FGT on a separate testing occasion, indicates diabetes.

Gestational diabetes is diagnosed with the OGTT. Glucose levels are normally lower during pregnancy, so the threshold values for diagnosis are proportionally lower. The presence of two plasma glucose values meeting or exceeding any of the following levels results in a diagnosis of gestational diabetes: a fasting plasma glucose level of 95 mg/dL, a one-hour level of 180 mg/dL, a two-hour level of 155 mg/dL, or a three-hour level of 140 mg/dL. Some practices deem a 1.7 oz (50 g) glucose solution with one-hour testing to be acceptable.

The hemoglobin A1c (HbA1c) test is used primarily to monitor the quality of glucose control over several weeks. Controlled blood glucose helps to minimize the development of complications caused by chronically elevated glucose levels, such as progressive damage to body organs. The HbA1c test is an overall picture of the average amount of glucose in the blood over the previous few months. HbA1c is the term for glycosylated (glucose-carrying)

hemoglobin in red blood cells. It is a measurement of how successful the employed treatments are at controlling blood sugar values. The HbA1c test can determine how severe blood sugar fluctuations have been in newly diagnosed diabetics and indicate the need for treatment adjustments in the medication or diets of known diabetics. Physicians may perform HbA1c tests on a patient several times a year to verify that good control is being maintained. The HbA1c test will not reflect temporary, acute fluctuations in blood glucose. A 1% change in HbA1c reflects a fluctuation of approximately 30 mg/dL in average blood glucose. An HbA1c value of 6% corresponds to an average blood glucose value of 135 mg/dL, while an HbA1c of 9% corresponds to an average blood glucose value of 240 mg/dL. The closer the HbA1c can be kept to 5% or 6%, the better diabetic control. Risk of diabetic complications increases with increased values of HbA1c.

A urinalysis followed by a blood test for ketones and pH is used in diagnosing ketoacidosis. Type I diabetes may also require a test for insulin level to determine whether it is very low or absent. A test for C-peptide levels, a byproduct of insulin production, is also often performed.

Treatment

After a diagnosis of type I diabetes, the immediate goals of treatment are to control blood glucose levels and control diabetic ketoacidosis, if present. Type I diabetics often have a sudden onset of severe symptoms that may require hospitalization. The ongoing goals of treatment are to prolong life, reduce symptoms, and prevent diabetes-related complications. Medication, education, weight control, exercise, foot care, and self-testing of blood glucose levels are key to a good prognosis.

Insulin lowers blood sugar by allowing it to leave the blood and enter the cells to be used as energy. Type I diabetics are insulin deficient and so must take insulin every day. Insulin is either injected under the skin at set times using a syringe, or administered by an infusion pump that delivers the insulin continuously. Insulin is not available as an oral medication. There are different types of insulin that vary in how quickly they work and the duration of their effect. More than one type of insulin is sometimes mixed together in an injection. Injections are usually self-administered from one to three times daily. Type I diabetes requires that food intake is balanced by insulin intake to prevent extreme fluctuations in blood glucose.

In March of 2005, the FDA approved Symlin, the first non-insulin drug for the treatment of adult type I diabetes. Symlin is intended as an addition to insulin therapy for three hours after meals when blood glucose control is not tight enough on insulin alone. Symlin is injectable and can be used to augment treatment of both type I and type II diabetes. Appropriate use of Symlin involves close monitoring by a physician to prevent hypoglycemic attacks. However, the addition of Symlin to the therapeutic environment is hoped to result in much tighter overall control in diabetics for whom current therapies are inadequate.

After a diagnosis of type II diabetes, the immediate goals are to eliminate symptoms and stabilize blood glucose levels. The ongoing goals are to prevent complications and prolong life. The primary treatment for type II diabetes is physical activity, weight control, and diet. Non-insulin oral medication is sometimes indicated to assist in lowering blood sugar when diet and exercise are not enough. These oral medications are effective in type II diabetics, but not type I diabetics.

There are multiple classes of medication available for treatment of type II diabetes. Oral sulfonylureas trigger the pancreas to increase insulin production. Biguanides (metformin) cause a decrease in liver glucose production to bring down blood glucose levels, while alpha-glucosidase inhibitors (acarbose) decrease the absorption of carbohydrates from the digestive tract, thereby lowering blood glucose levels after meals. Thiazolidinediones (rosiglitazone) assist insulin functioning at the cell surface by increasing the responsiveness to insulin. Meglitinides (repaglinide and nateglinide) trigger the pancreas to increase the proportion of insulin released in response to blood glucose. Type II diabetics who continue to have poor blood glucose control despite lifestyle changes and the use of oral medicines may be prescribed insulin treatment. Type II diabetics are also sometimes prescribed insulin treatment if they cannot tolerate the oral medications. Insulin must be injected under the skin using a syringe and cannot be taken orally.

For all types of diabetes, planning balanced meals and dietary control requires education. Regular physical activity is important to help control blood glucose and weight. However, diabetics must take special precautions before engaging in intense physical activity that may alter blood glucose levels too rapidly. Blood glucose monitoring is done with specialized home kits called glucometers. A glucometer is a small device that provides an exact reading of blood glucose. A test strip is used to collect a small drop of blood obtained by pricking the finger with a small needle called a lancet. The test strip is placed in the meter and results are available within 30–45 seconds. Testing is done on a regular basis to monitor the balance between food intake, medication, and physical activity. Test results may are used to adjust meals, activity, and medications to keep blood glucose under control. Diabetes causes damage to the blood vessels and nervous system that often results in a loss of sensation to the foot. Foot injuries may go unnoticed until severe infection develops due to lack of care and a depressed immune system. A daily foot care routine involves washing and inspecting the feet, and generally keeping them clean and dry.

Hypoglycemia, or low blood glucose, can occur in diabetics when they use too much insulin, drink alcohol, exercise too much, or eat too little food. Symptoms of low blood sugar typically appear when blood glucose levels fall below 70. Treatment involves eating something with sugar such as fruit juice. Sugar intake should be continued until blood glucose control is achieved. Only after blood glucose has returned to normal should more substantial food be eaten. Severe hypoglycemia may require a shot of glucagon at a hospital emergency room.

Ketones can be monitored using a simple urine test available at pharmacies. Warning signs for ketoacidosis include flushed face, dry skin and mouth, nausea or vomiting, stomach pain, deep, rapid breathing, or fruity breath odor. If left untreated, the condition can worsen and lead to death. Treatment of DKA involves lowering the blood glucose level to normal, and to replacing fluids lost through excessive urination and vomiting. It is often possible to recognize the early warning signs of DKA and make appropriate corrections at home before the condition progresses. If severe DKA develops, hospitalization is often required to control the condition. immunizations. Diabetes education is critical to the treatment plan.

Prognosis

Diabetes is a chronic disease for which there is not yet a cure. The prognosis for diabetics is varied based on blood glucose control. Tight control of blood glucose can delay or even prevent the progression of complications and secondary illnesses caused by diabetes. However, complications may occur even when good control is achieved. Diabetics with high control of blood glucose and blood pressure significantly reduce their risk of death, stroke, and heart failure. A reduction of HbA1c by one percentage point can improve prognosis and cause a decrease in the risk for complications by 25%. Prognosis is greatly improved by a normal BMI, which uses individuals' height and weight to rate them as normal, overweight, or obese. A score of 18–24.9 is considered normal and improves the prognosis for diabetes. A score of 25–29.9 indicating overweight, or a score of 30 or more indicating obesity, results in a poorer prognosis. Diabetics have increased susceptibility to illness such as influenza. Once a diabetic has an illness, they often have a worse prognosis than non-diabetics. Smoking cigarettes drastically worsens the prognosis for diabetes, greatly increasing the risk of vascular complications, gangrene, and amputations.

Resources

BOOKS

Champe, P. C., and R. A. Harvey. Lippincott's Illustrated Review of Biochemistry, Second Edition. Philadelphia, PA: Lippincott, 1994.

Thompson & Thompson Genetics in Medicine, Sixth Edition. St. Louis, MO: Elsevier Science, 2004.

WEBSITES

All About Diabetes. American Diabetes Association. (April 2, 2005.) <http://www.diabetes.org/genetics.jsp>.

Diabetes. Centers for Disease Control and Prevention. (April 2, 2005.) <http://www.cdc.gov/diabetes/>.

Diabetes. MedlinePlus. (April 2, 2005.) <http://www.nlm.nih.gov/medlineplus/diabetes.html>.

Diabetes. National Diabetes Information Clearinghouse. (April 2, 2005.) <http://diabetes.niddk.nih.gov/dm/a-z.asp>.

Diabetes Data and Trends. Centers for Disease Control and Prevention. (April 2, 2005.) <http://www.cdc.gov/diabetes/statistics/index.htm>.

Diabetes Health Topics. Centers for Disease Control and Prevention. (April 2, 2005.) <http://www.cdc.gov/doc.do/id/0900f3ec802723eb>.

The Genetic Landscape of Diabetes. National Institutes of Health. (April 2, 2005.) <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=diabetes.TOC&depth=1>.

ORGANIZATIONS

American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. 800-DIABETES, (800) 342-2383. (April 2, 2005.) <http://www.diabetes.org>.

National Diabetes Education Program. (800) 438-5383. (April 2, 2005.) <http://www.cdc.gov/diabetes/ndep/index.htm>.

National Diabetes Information Clearinghouse. 1 Information Way, Bethesda, MD 20892-3560. (800) 860-8747. (April 2, 2005.) <http://diabetes.niddk.nih.gov/about/index.htm>.

Maria Basile, PhD

More From encyclopedia.com